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1. Introduction  
Fanconi anemia (FA) is a chromosomal instability syndrome characterized by various 
congenital malformations, progressive pancytopenia, chromosome breakage and 
predisposition to malignancy (Alter, 2003a). Autosomal recessive, FA is also inherited with 
X-linked inheritance reported in FA complementation group B (Meetei et al., 2004). FA 
pathway controls genomic stabilisation in mammalian cells and is referred to as FA pathway 
of antioncogenesis. Children with FA have a very high risk of developing acute myeloid 
leukemia (AML) and myelodysplastic syndrome (MDS). The incidence of AML in children 
with FA is 15.000 times that of children in the general population (Auerbach & Allen, 1991). 
Acute leukemia is the terminal event in about 5-20% of these cases (Ebell et al., 1989), MDS 
in about 5-10%, and solid tumors was held responsible in about 5-10% of the remaining 
cases. Patients with FA are at a high risk of developing solid tumors of the head, neck, 
esophagus, liver and female genitalia (Alter, 2003c, Rosenberg, Greene & Alter, 2003). In 
order to clarify the relationship between FA and cancer, the description of FA was recently 
updated as “an inherited genomic instability disorder, caused by mutations in genes 
regulating replication-dependent removal of interstrand DNA crosslinks” (Moldovan & 
D’Andrea, 2009). The research on the complex roles of FA proteins in repairing DNA 
improved our understanding of cancer biology. In this chapter, my main objective is 
twofold: to analyze clinical findings, diagnosis and hematological characteristics of FA, and 
to evaluate the relationship between FA pathway and cancer from the perspective of a 
pediatrician.  
2. Fanconi anemia 
FA is a familial pancytopenia associated with bone marrow hypoplasia and congenital 
malformations, originally discovered in three brothers by Fanconi in 1927 (Gözdaşoğlu et 
al., 1980). 2000 cases were reported in the literature between the years of 1927 and 2009 
(Alter, 2011). FA should be considered a syndrome, not a disease due to its heterogeneity.   
The physical phenotype ranges from normal appearance to manifest congenital 
malformations, the hematological spectrum ranges from nominal values to those associated 
with severe aplastic anemia (Alter, 1993b). Clinical heterogeneity in FA follows from genetic 
heterogeneity. The heterozygote prevalence for FA is estimated to be 1 in 300 in the United 
States (Alter, 1993a). Homozygote frequency is estimated at 1-3 per million (Joenje et al., 
1995). The male-female ratio of occurrence is 1.2:1 (Alter, 2003a). The age of diagnosis ranges 
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from birth to 48 years with an average of 8 years. About 10-20% of families have 
consanguineous marriage (Alter, 1992).  
2.1 Congenital abnormalities  
Several congenital abnormalities may accompany this disorder such as skeletal 
abnormalities, hyperpigmentation, renal malformation, microcephaly, hypogonadism and 
mental and growth retardations (Gözdaşoğlu et al., 1980; Akar & Gözdaşoğlu, 1984). Among 
skeletal system anomalies, radial ray defects such as hypoplasia of the thumb and the radius 
are observed most (Figures 1, 2, 3). In addition to congenital hip dislocations, scoliosis, 
vertebral anomalies, cafe-au-lait spots, diffuse hyperpigmentation and hypopigmentation 
are frequent. A short stature is prominent in more than half of the cases in utero and 
following birth. The median height is about 50 percentile in the patients, which can be 
related to growth hormone deficiency or hypothyroidism. Mycrophtalmia, microcephaly 
and deafness may be observed, renal anomalies such as unilateral and renal aplasia, renal 
hypoplasia, horse-shoe kidney and double ureter may be encountered in about a third of the  
cases. Boys have genital anomalies as hypogenitalia, undescended testis and hypospadias.  
Girls have uterus anomalies. There have been reports of gastrointestinal defects such as 
esophageal, duodenal atresia, imperforated anus, tracheo-esophageal fistula, cardiac defects 
such as patent ductus arteriosus, ventricular septal defect, pulmonary stenosis, aortic 
stenosis, aortic coarctation, central nervous system anomalies such as hydrocephalus and 
absence of septum pellucidum (Alter, 2003b; Kwee & Kuyt, 1989; Smith et al., 1989). The FA 
phenotype can vary within family members; a report of four FA cases within two related 
consanguineous families who all had the same FANCA mutation demonstrated a wide 
variation in birth weight, skin pigmentation and the severity of skeletal, renal and genital 
abnormalities (Koç et al., 1999). Approximately 25-40% of the FA patients in the 
International Fanconi Anemia Registry (IFAR) do not exhibit any major malformation 
(Alter, 2003a).  
 
 
 
 
   
 
 
Fig. 1. a) The picture of a 6-year-old girl with Fanconi anemia showing hypoplastic and 
proximally placed rudimentary thumbs, clinodactyly. b) Sprengel deformity and scoliosis. 
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Fig. 2. The picture of a 10-year-old boy with aplastic anemia showing the absence of 
radius and thumb on the right hand, hypoplastic thumb on the left hand and 
hypogenitalismus. 
 
 
Fig. 3. Bifid left thumb and proximally placed right thumb. 
2.2 Hematologic abnormalities 
In homozygote FA, the most prominent finding is hematologic disorders. The blood count 
at birth is mostly normal and macrocytosis is generally the first sign of FA. This is 
followed by thrombocytopenia and anemia. Pancytopenia develops typically at 5-10 years 
of age, median at seven years (birth to 31 years) (Butturini et al., 1994). IFAR defined 
hematologic abnormality as hemoglobin level below 10 g/dL, absolute neutrophil count 
below 1x109/L or platelet count below 100 x 109/L (Alter et al., 2003a). On retrospective 
analysis of 145 FA patients, some congenital anomalies were seen to carry a potential risk 
of the development of bone marrow failure. The risk of bone marrow failure in those with 
radius anomaly is 5.5 times more than those without. The presence of abnormal head, 
deafness, developmental delay, cardiopulmonary abnormality and abnormal kidney, also 
kown as 5-item congenital abnormality, increase the risk of bone marrow failure 
(Rosenberg et al., 2004). 
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Hematologic disorders are the first sign of FA in young adults not exhibiting any congenital 
anomalies. Stress erythropoesis exists in FA with characteristics of macrocytosis, increased 
HbF and the antigen i (Table 1). These characteristics may also be found in the anemia free 
siblings of FA patients (Alter, 2003a). Aspiration from bone marrow reveals marked 
depression or absence of hematopoietic cells and replacement by fatty tissue containing 
reticulum cells, lymphocytes, plasma cells and usually tissue mast cells. Nucleated red cells 
are also decreased in number and they may display megaloblastic features (Fig. 4). Bone 
marrow biopsy is essential for diagnosis (Lanzkowsky, 1999). In a study based on data from 
388 cases with FA, actuarial risk of developing hematopoietic abnormalities was 98% by the 
age of 40 (Butturini et al., 1994). 
 
 Stress erythropoesis 
- macrocytosis 
- Hb F  
- Antigen i 
 Trombocytopenia, anemia 
 Pancytopenia median age: 7 years (5-10 years) 
 Bone marrow failure in radius aplasia; 5.5  
Table 1. Hematological findings in FA. 
 
 
Fig. 4. Fatty tissue and mast cells in the bone marrow. 
The most striking feature of FA cells is an increased spontaneous chromosomal instability. 
Diepoxybutane (DEB) test remains a classical test for diagnosis, involving the detection of 
chromosomal breaks, gaps, rearrangements, radials, exchange and endoreduplications in 
peripheral lymphocytes following culturing with clastogenic agents (such as DEB or 
mitomycin-C) (Fig. 5a, b) (Auerbach et al., 1981). FA homozygotes have a mean of 8.96 
breaks per cell in the DEB test according to the IFAR (Alter, 2003a).  
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Fig. 5. a) Chromosomal structure abnormalities in the patient with FA. Arrow indicates 
typical quadriradial chromosome. b) Cytogenetic abnormalities in the metaphase plaque. 
Arrow indicates chromatid breaks and fragmentation. 
Interpretation of the results of DEB test may be complicated by mosaicism. Approximately 
25% of patients with FA have evidence of spontaneously occurring mosaicism as manifest 
by the presence of two subpopulations of lymphocytes, one of which is hypersensitive to 
cross-linking agents while the other behaves normally in response to these agents. 
Mosaicism might be associated with a relatively mild hematological course (Lo Ten Foe et 
al., 1997). DEB test gives a false negative for these patients. DEB testing to establish the 
diagnosis could be performed on an alternative cell type, such as skin fibroblasts (Alter & 
Kupfer, 2011). Although DEB test is of crucial importance in the diagnosis of FA, it should 
be also noted that molecular genetic diagnostic methods have also started to be used in the 
identification of this disorder. 
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2.3 Cellular disorders and hematopoiesis  
Patients with FA generally develop some degree of bone marrow dysfunction ranging 
from mild asymptomatic cytopenias in any lineage to severe aplastic anemia, MDS or 
AML. The absence of marrow failure does not rule out FA (Shimamura, 2003). A number 
of cytokines are critical in the control and regulation of cellular homeostasis in bone 
marrow. Several cellular disorders associated with FA were reported in a large number of 
studies. FA cells have important phenotypic abnormalities related to hematopoiesis as 
shown in Table 2. 
 
 
 
Sensitivity to cross- linking agents  
Prolongation of G2 phases of cell cycles 
Sensitivity to oxygen  
Sensitivity to ionized radiation 
Overproduction of tumor necrosis factor- 
Direct defects in DNA repair: 
- Accumulation of DNA adducts 
- Defect in repair DNA cross links 
Genomic instability 
- Spontaneous chromosome breakage 
- Hypermutability  
Increased apoptosis 
Defective p53 induction 
Intrinsic stem cell defect 
Decreased colony growth   
 
 
Table 2. Cellular disorders in FA (From Lanzkowsky, P. Manual of Pediatric Hematology 
and Oncology 1999). 
Defective hematopoiesis in FA was shown by the investigation of in vitro bone marrow 
cell cultures. Interleukin (IL)-6 and granulocyte macrophage-colony stimulating factor 
expression reduced in many patients with FA (Stark et al., 1993). In another research, the 
overproduction of tumor necrosis factor- in FA was also reported (Schultz & Shahidi, 
1993). On the other hand, these patients have increased loss of telomere signals compared 
with controls (Hanson et al., 2001). Abnormal telomere metabolism might play a role in 
the evoluation of bone marrow failure and malignant transformation in FA (Li et al., 
2003). The cytokine changes, increased apoptosis and telomere shortening play a 
significant role in the microenvironment of bone marrow and the regulation of cellular 
homeostasis (Fig. 6). Bone marrow failure occurs at a median age of 7 years. 
Hematopoietic tissue is particularly sensitive to DNA damage caused by radiation or 
cytotoxic drugs. Genome instability and telomere shortening alter the signals and form 
mutant clones resistant to apoptosis and consequently AML develops (Lensch et al., 1999; 
Tischkowitz & Dokal, 2004). 
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Fig. 6. Defective Hematopoiesis in FA (Adapted from Lensch et al., 1999 and Tischkowitz & 
Dokal, 2004). 
The role of p53 in preventing DNA damage in FA cells was shown in a theoretical model 
(Kennedy & D’Andrea 2005). As revealed in Fig. 7, when severe DNA damage occurs in FA 
cells, p53 activates apoptosis and tumor progression is inhibited. If this process occurs in 
embryonic stem cells, it may cause anomalies. Stem cell loss in bone marrow leads to 
progressive anemia associated with FA.  
 
 
Fig. 7. p53-mediated apoptosis (From Kennedy, R.D. & D’Andrea, A.D., The Fanconi 
Anemia/BRCA Pathway: New Faces in the Crowd. Genes and Development, 2005; 19:2925-
2940). 
Loss of p53 or other genes related to apoptosis due to DNA breakage by viral infection or 
cross-link agents, might inhibit the cell apoptosis. Cells with severe DNA damage continue 
dividing and this, in turn, may result in malignant transformation. Also a tumor may 
develop with human papilloma virus (HPV) infections. Since HPV E6 protein decreases the 
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p53 protein level, the apoptotic pathway activation is inhibited. Loss of p53 function may 
lead to cancer by allowing premalignant cells to survive (Kennedy & D’Andrea 2005). 
2.4 Complementation groups, genes and DNA repair  
Fifteen complementation groups have been identified in patients with FA (Table 3) and new 
complementation groups may be identified in the future.  
 
Complementation group gene frequency* % chromosome 
FA – A FANCA 60 16q 24.3 
FA – B FANCB <1 Xp 22.3 
FA – C FANCC 15 9q 22.3 
FA – DI BRCA2 <5 13q 12.3 
FA – D2 FANCD2 <5 3p 25.3 
FA – E FANCE <1 6p 21.3 
FA – F FANCF <1 11p 15 
FA – G FANCG 10 9p 13 
FA – I FANCI <1 15q 25 - q 26 
FA – J BRIP1 <1 17q 22 
FA – L FANCL <1 2p 16.1 
FA – M FANC M <1 14q 21.3 
FA – N PALB2 <1 16p 12 
FA – O RAD51C <1 17q 22 
FA – P SLX4 <1 16p 13.3 
Table 3. FA complementation groups and genes (Adapted from Alter & Kupfer, 2011; 
Kennedy & D’Andrea, 2005). 
FA-A mutations are the most frequent ones observed in about 60% of the cases; FA-C and 
FA-G mutations are recognized in 15% and 10% of the cases, respectively. While the 
frequencies of FA-D1 (BRCA2) and FA-D2 are 5% each, the prevalence of other 
complementation groups is rare (Kennedy & D’Andrea, 2005). The first gene cloned is the 
FA-C complementation group gene composed of 1674 nucleotides and 14 exons (Fig. 8). Six 
mutations are recognized in the gene. More than 90% of FA-C mutations are in exon 1 and 
in exon 4. There is a mild form of FA in mutation related with “dG 322” deletion in exon 1. 
IV S4 + 4A > T mutations are distinguished for the majority of FA in Ashkenazi Jewish 
patients having severe phenotype of multiple congenital malformations and early onset of 
hematological disease (Joenje et al., 1995a, 1995b).  
 
 
Fig. 8. Mutations in FA-C gene (From Joenje, H. et al., Fanconi Anemia Research: Current 
Status and Prospects, European Journal of Cancer 1995; 31:268-272). 
Q13X dG322 IVS4+4A>T R185X D195V* 
S26F G139E 
5’UTR 1 2 3 4 5 6 7 8 9 10 11 12 13 14 3’UTR 
R548X L554P 
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Several types of, sometimes overlapping, DNA repair processes are identified based on the 
targeted types of damage. Three types of excision repair processes have been described: base 
excision repair (BER), nucleotide excision repair (NER) and mismatch repair (MMR). Two 
additional types of DNA repair, homologous recombination (HR) and nonhomologous end-
joining (NHEJ) are employed in response to a double strand break, the most serious type of 
DNA damage. HR is considered to be an error-free pathway since it uses a copy of the 
damaged segment. NHEJ is accepted as an error-prone pathway since free ends are joined in 
the absence of a template which might cause an associated loss of nucleotides or 
translocation (Risinger & Groden, 2004). FA pathway has an important role in three classic 
DNA repair processes, namely homologous recombination, nucleotide excision repair 
andtranslesion synthesis  which is DNA polymerization on damaged templates (Moldovan 
& D’Andrea, 2009).  
FA proteins have a significant role in regulating DNA repair by homologous recombination. 
FA proteins cooperate in a common pathway known as the FA/BRCA pathway. Eight of the 
FA proteins (A, B, C, E, F, G, L, M and possibly I subunits) form a nuclear core complex 
required for the monoubiquitination of FANCD2 protein. In response to DNA damage, the 
FA complex (complex 1) is activated and initiates the monoubiquitination of FANCD2. Then 
FANCD2 – Ub interacts with BRCA2 in complex 2, leading to repair of the cross-link 
possibly through homologous recombination and translesion synthesis. The FANCD1 gene 
is identical to the breast and ovarian cancer susceptibility gene, BRCA2. FANCD2 is 
deubiquitinated by USP1, thereby inactivating the pathway (Fig. 9). The FA proteins are also 
important in the arrangement of an intra-S-phase checkpoint (D’Andrea, 2003; Kennedy & 
D’Andrea, 2005; Wang & D’Andrea, 2004). In the absence of BRCA2, DNA repair cannot be 
performed by homologous recombination. DNA damage is repaired by nonhomologous 
end-joining (Fig. 10). 
 
 
Fig. 9. The FA pathway (From Kennedy, R.D. & D’Andrea, A.D., The Fanconi 
Anemia/BRCA Pathway: New Faces in the Crowd. Genes and Development 2005; 19: 2925-
2940). 
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Fig. 10. Repair of double-strand break in normal and FA cells (Adapted from Venkitaraman, 
2004). HR: Homologous recombination; NHEJ: Nonhomologous end-joining. 
In the cytoplasm, only FANCA, FANCC, FANCF and FANCG proteins are present. 
Cytoplasmic functions and interactions of FANCC and FANCG are decoded. The FANCC 
protein binds to NADPH cytochrome P-450 reductase and regulates the major detoxification 
pathway. FANCC also interacts with glutathion-S-transpherase PI-I, and protects the cell 
from oxidative stress. FANCC interacts with HSP70 to prevent the apoptosis in 
hematopoietic cells exposed to IFN–γ and TNF-α. FANCC is required for optimal activation 
of STAT1 in the JAK/STAT pathway. FANCG protein directly interacts with CYP2E1 and 
prevents oxidative DNA damage (Thompson et al., 2005).  
2.5 Fanconi anemia and cancer 
Mutations in FA genes cause a disorder characterized by bone marrow failure, 
developmental defects and cancer proneness (Moldovan & D’Andrea, 2009). The FANCD2 
knockout mice exhibit micropthalmia, perinatal lethality, and severe hypogonadism. 
Fancd2knockout mice also has increased incidences of epithelial cancers such as breast, 
ovarian and liver cancers (D’Andrea, 2003). FA is a rare cancer susceptibility syndrome that 
increases the predisposition of the patient to leukemia, squamous cell carcinomas of the 
head and neck or female genitelia as well as liver tumors. Predisposition to cancer in 
heterozygotes was also reported by Swift (Alter, 2003a). One thousand three hundred cases 
of FA were evaluated during the years between 1927 and 2001. Nine percent of these cases 
had leukemia, 7% had myelodysplastic syndrome, 5% had solid tumors and 3% liver 
tumors. In approximately 25% of patients with cancer, the malignancy preceded the 
diagnosis of FA. It is unclear which patients are prone to develop such tumors (Alter, 2003c). 
In another study, the cumulative incidence of malignancies among 145 patients with FA was 
9 leukemias and 18 solid tumors in 14 patients. The ratio of observed to expected neoplasm 
(O/E) was 50 for all cancers, 48 for all solid tumors and 785 for leukemia. These increased 
risks were calculated to be statistically significant. The highest solid tumor O/E ratios were 
4317 for vulvar cancer, 2362 for esophageal cancer, and 706 for head and neck cancer. The 
median age of onset of leukemia was 11.3 years, which is significantly lower compared to 
the median 28.9 years of onset for solid tumors (Rosenberg et al., 2003). Actuarial risk of 
developing MDS or AML by 40 years of age was 52% (Butturini et al., 1994).  
Double-strand break Double-strand break 
Repair with 
HR 
Repair with 
NHEJ 
NORMAL CELLS FA CELLS  
(FA/BRCA-PATHWAY DEFECTIVE) 
Repair with 
HR 
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The types of leukemia occurring in FA are primarily non-lymphocytic leukemia although a 
few lymphoblastic types have also been reported (Alter, 1993a; Yetgin et al., 1994). The 
incidence of AML in FA patients is 15.000 times more compared to children in the 
population (Auerbach & Allen, 1991). In these patients, all FAB sub-types occur; the 
myelomonocytic (M4) and acute monocytic (M5) types (Fig.11, Fig.12) are the most common 
(Alter, 2003c, Tischkowitz & Dokal, 2004).  
Certain cytogenetic abnormalities are commonly seen in these patients with MDS/AML. In 
one study of the cytogenetic findings of 23 MDS and AML cases in FA homozygotes in high 
incidence of monosomy 7, 7q-, rearrangement of 1p36, 1q24-34 and 11q22-25, abnormalities 
was reported (Butturini et al., 1994). The most frequently observed chromosomal 
abnormalities in FA-associated leukemia are monosomy 7, duplication of 1 q and 
chromosome 3q abnormalities. Gain of 3q is associated with poor prognosis (Taniguchi & 
D’Andrea, 2006).  As suggested, all FA patients may be considered as preleukemic state and 
this disorder represents a model for study of the etiology of AML (Auerbach & Allen, 1991). 
Leukemia may be the first hematologic manifestation of FA (Auerbach et al., 1982). Five out 
of the 52 patients with FA developing 3 AML, 1 squamous cell carcinoma of the gingiva, 1 
hepatocellular carcinoma were mentioned in another clinical  research (Altay et al., 1997). 
 
 
Fig. 11. Auer rods positivity in myeloblast. 
 
Fig. 12. Monoblasts in the bone marrow. 
In our series, four out of 39 cases developed AML and one had two malignancies.There were 
no other cancers among family members in these four patients whereas the sister of a boy with 
FA developed acute leukemia in another hospital. (Gözdaşoğlu et al., 1980, Gözdaşoğlu et al., 
2009). The majority of solid tumors occurs after the first or second decade of life (Alter, 2011).  
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FA-D1 complementation group is different from other complementation groups in its 
severity. In this group, leukemia and solid tumors develop as early as before 5 years of age. 
A cell line (termed FA-AML1) was obtained from blast cells after a second relapse following 
the bone marrow transplantation in a 2 years old boy with FA and AML. FA-AML1 is the 
first AML cell line obtained from a FA patient. FA-AML1 cells have failed to reveal FA 
phenotype such as hypersensitivity to growth inhibition and chromosomal breakage by the 
cross-linking agent mitomycin C. Genomic DNA showed biallelic mutations in 
FANCD1/BRCA2. Genetic reversion has been observed resulting in the loss of the FA 
cellular phenotype (Ikeda et al., 2003). In another report, a cross-linker-sensitive AML cell 
line also was derived from a 2 years old boy who had biallelic FANCD1/BRCA2 (Meyer et 
al., 2005). FA-D1 subgroup, however, can be associated with a high incidence of leukemia 
and specific solid tumors such as Wilms tumor and medulloblastoma in very early 
childhood (Hirsch et al., 2004). BRCA2 mutations predisposes to cancers like the familial 
breast, ovary, prostate and pancreas (Shivji & Venkitaraman, 2004). From several studies on 
the issue, it is possible to conclude that the diagnosis of leukemia and solid tumors at early 
age and worse prognosis are the most important features of FA-D1 complementation group. 
FA is found as the most common form of inherited bone marrow failure syndrome 
associated with worst prognosis. A high percentage of patients developed severe bone 
marrow failure and cancer  in a study based on 127 patients whose 66 cases (52%)  are with 
FA. One of the striking findings of this study is the high rate of consanguinity, 68 % of 
patients with FA. Leukemia in 7 patients (11%), MDS in 11 patients (16%) and solid tumors 
in 6 patients (9%) out of these 66 cases were diagnosed (Tamary et al., 2010). In another 
study of 181 patients, however, bone marrow failure in 66 patients, acute myeloid leukemia 
in 14 patients and solid tumors in 10 patients were determined. The ratio of O/E was 44 for 
all cancers, 26 for all solid tumors and 868 for acute myeloid leukemia. These increased risks 
were statistically significant. In this study, absent or abnormal radii and a five-item 
congenital abnormality score were significant risk factors for bone marrow failure.  In three 
of the 48 patients who received a transplant, the three malignancies, namely tongue, liver 
and esophagus, occurred after 2, 16 and 17 years following the transplants. The age-specific 
risk of solid tumors was 3.8-fold higher in cases with transplants compared to the cases 
without (Rosenberg, Alter & Ebell, 2008). Hematopoietic stem cell transplant (HSCT) is 
presently the only therapy that can restore normal hematopoiesis in patients with FA. The 
risk of squamous cell cancers increased for FA patients irrespective of receiving and not 
receiving the transplants. HSCT conditioning regimes may also increase the occurrence of 
squamous cell cancers in cases with transplants. Rosenberg et al., compared two groups of 
patients; 117 receiving transplants and 145 not receiving. It was found that the age-specific 
risk of squamous cell cancer was 4.4 fold higher in patients who received transplants than 
who did not. Squamous cell cancers developed at significantly younger ages in the 
transplanted group. Acute and chronic graft-versus-host diseases were significant squamous 
cell cancer risk factors, and this cancer was also an adverse risk factor for death in both 
groups. Survival rate following squamous cell cancer was not significantly different 
between the two groups (Rosenberg et al., 2005). Liver tumors associated with androgens 
were reported in the patients with FA (Velazquez& Alter, 2004) and the cumulative 
probability of liver tumors has been estimated to be 46 % by age 50 (Alter, 2003c). 
The patients with FA should be followed in the form of hematologic monitoring and cancer 
surveillance. Complete blood counts should be taken every 4 months. Annual bone marrow 
aspirates and biopsies should be performed on all patients. Dental and oropharyngeal( 
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including naso-laryngoscopy) exams should start at age 10 or within the first year after 
transplant. Gynecologic examination and Pap semears beginning at age 16, and if necessary, 
annual esophageal endoscopy should be done as part of  cancer surveillance. The patients 
are advised to avoid toxic agents, smoking and alcohol. Radiographic studies should be 
minimally utilised. Vaccination of female patients with the human papillomavirus vaccine 
should be considered starting at nine years of age (Alter,2011). 
3. Conclusion 
FA is a rare autosomal recessive or x-linked inherited chromosomal instability syndrome. 
Affected individuals have a highly increased risk of developing bone marrow failure, 
hematologic malignancies and solid tumors. FA-pathway has an important role in repairing 
DNA damage namely homologous recombination, nucleotide excision repair and 
translesion synthesis. Fifteen complementation groups and genes that cause FA have been 
identified. FA-D1 subgroup can be associated with high incidence of leukemia and solid 
tumors such as Wilms tumor, medulloblastoma, neuroblastoma at early ages.  BRCA2 
mutations predispose to cancers such as familial breast, ovary, prostate and pancreas. 
Leukemia in FA is generally very difficult to treat and survival is rare. The deficiency in 
DNA repair leads to increased sensitivity to the side effects of chemotherapy and the 
patients are either vulnerable to treatment toxicity or may receive inadequate treatment. The 
effective treatment modalities have to be further developed. Patients with FA should be 
followed with regard to AML and solid tumors which should be considered as first 
manifestations of FA. It is also important to note that the family members of the patients 
with FA must be scanned for cancer as well. Genetic counseling and psychosocial support 
should be employed as soon as possible. 
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